title: Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans.
abstract: Pharmacokinetic-pharmacodynamic (PK-PD) modeling greatly enables quantitative implementation of the "learn and confirm" paradigm across different stages of drug discovery and development. This work describes the successful prospective application of this concept in the discovery and early development of a novel κ-opioid receptor (KOR) antagonist, PF-04455242, where PK-PD understanding from preclinical biomarker responses enabled successful prediction of the clinical response in a proof of mechanism study. Preclinical data obtained in rats included time course measures of the KOR antagonist (PF-04455242), a KOR agonist (spiradoline), and a KOR-mediated biomarker response (prolactin secretion) in plasma. Clinical data included time course measures of PF-04455242 and prolactin in 24 healthy volunteers following a spiradoline challenge and single oral doses of PF-04455242 (18 and 30 mg). In both species, PF-04455242 successfully reversed spiradoline-induced prolactin response. A competitive antagonism model was developed and implemented within NONMEM to describe the effect of PF-04455242 on spiradoline-induced prolactin elevation in rats and humans. The PK-PD model-based estimate of K(i) for PF-04455242 in rats was 414 ng/mL. Accounting for species differences in unbound fraction, in vitro K(i) and brain penetration provided a predicted human K(i) of 44.4 ng/mL. This prediction was in good agreement with that estimated via the application of the proposed PK-PD model to the clinical data (i.e., 39.2 ng/mL). These results illustrate the utility of the proposed PK-PD model in supporting the quantitative translation of preclinical studies into an accurate clinical expectation. As such, the proposed PK-PD model is useful for supporting the design, selection, and early development of novel KOR antagonists.
authors.affiliation: Pharmacokinetics, Dynamics and Metabolism, Worldwide Research & Development, Pfizer Inc., Groton, Connecticut, USA. cheng.chang@pfizer.com
authors.forename: Cheng
authors.initials: C
authors.lastname: Chang
authors.forename: Wonkyung
authors.initials: W
authors.lastname: Byon
authors.forename: Yifeng
authors.initials: Y
authors.lastname: Lu
authors.forename: Leslie K
authors.initials: LK
authors.lastname: Jacobsen
authors.forename: Lori L
authors.initials: LL
authors.lastname: Badura
authors.forename: Aarti
authors.initials: A
authors.lastname: Sawant-Basak
authors.forename: Emily
authors.initials: E
authors.lastname: Miller
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Sarah
authors.initials: S
authors.lastname: Grimwood
authors.forename: Ellen Q
authors.initials: EQ
authors.lastname: Wang
authors.forename: Tristan S
authors.initials: TS
authors.lastname: Maurer
mesh_terms: D000818:Animals; D001713:Biphenyl Compounds / Q000493:pharmacokinetics* / Q000494:pharmacology*; D002853:Chromatography, Liquid; D006801:Humans; D057230:Limit of Detection; D008297:Male; D008962:Models, Theoretical; D009292:Narcotic Antagonists / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000493:pharmacokinetics* / Q000494:pharmacology*; D053719:Tandem Mass Spectrometry
chemical_list: C568463:2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine; D001713:Biphenyl Compounds; D009292:Narcotic Antagonists; D017473:Receptors, Opioid, kappa; D013449:Sulfonamides